Altana submits roflumilast in Europe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daxas (roflumilast) marketing authorization application has been submitted to the European Medicines Evaluation Agency, Altana announces Feb. 13. In the U.S., the oral, once-daily, selective phosphodiesterase-4 inhibitor is in Phase III for treatment of chronic obstructive pulmonary disease and asthma with development partner Pfizer...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.